BERKELEY, Calif., July 25, 2017 -- Lygos, a leading innovator in developing sustainable high-value specialty chemicals, today announced that industry veteran Johan van Walsem will join as Chief Operations Officer. van Walsem brings more than 25 years of industry experience in bioprocess engineering and a demonstrated track record in developing, scaling up and commercializing advanced fermentation processes.
"Johan has extensive experience in the development and operation of fermentation-based manufacturing processes at commercial scale," said Eric Steen, CEO of Lygos. “As Lygos grows from pilot scale to commercial scale manufacturing, he ensures that this critical phase will be expertly managed by a proven industry expert. Johan will help us scale the fermentation processes required to manufacture our Bio-Malonate™ family of products in an environmentally-safe, cyanide-free, and cost-competitive manner."
van Walsem joins Lygos from Metabolix where he served as Chief Operating Officer and Vice President of Manufacturing and Product Development and led biopolymer and renewable chemicals business platforms enabled by fermentation technology. He was responsible for defining commercial strategy around high-value markets, establishing global supply chains for biopolymers, and developing advanced manufacturing technology to lower overall costs. He has more than 25 years of experience in the bioprocessing industry leading development and manufacturing efforts for large-scale, fermentation-based processes. He holds a Master's degree in Chemical Engineering from the University of Pretoria and an M.B.A. from the University of South Africa.
"Lygos offers a rare opportunity in its business growth prospects and the innovation of its technology platform for bio-malonates,” said van Walsem. “This is a unique platform that allows our customers to create even more value. I’m excited to join a team of top-notch scientists, engineers, and industry experts to help commercialize a truly ground-breaking technology."
About Lygos, Inc.
Lygos makes microbial-based manufacturing solutions at the juncture of biology and technology that create market-transforming product opportunities. Lygos' first products -- malonic acid and derivatives -- replace low-quality petrochemical products produced at high economic and environmental cost in countries without strong environmental protection programs. Lygos is venture-backed by 50 Years, First Round Capital, IA Ventures, OS Fund, Vast Ventures and the Y Combinator Continuity Fund, along with notable angel investors. Lygos' R&D was originally funded by the U.S. Department of Energy, U.S. Department of Agriculture, and the National Science Foundation. For more information, visit http://www.lygos.com or follow us on Twitter: @LygosBiotech.
Editorial Contact Lonn Johnston for Lygos [email protected] +1.650.219.7764


Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 



